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The 2-oxoglutarate (2OG)-dependent Jumonji C domain (JmjC)
family is the largest family of histone lysine demethylases.
There is interest in developing small-molecule probes that
modulate JmjC activity to investigate their biological roles. 5-
Carboxy-8-hydroxyquinoline (IOX1) is the most potent broad-
spectrum inhibitor of 2OG oxygenases, including the JmjC de-
methylases, reported to date; however, it suffers from low cell
permeability. Here, we describe structure–activity relationship
studies leading to the discovery of an n-octyl ester form of
IOX1 with improved cellular potency (EC50 value of 100 to
4 mm). These findings are supported by in vitro inhibition and
selectivity studies, docking studies, activity versus toxicity anal-
ysis in cell cultures, and intracellular uptake measurements.
The n-octyl ester was found to have improved cell permeabili-
ty; it was found to inhibit some JmjC demethylases in its intact
ester form and to be more selective than IOX1. The n-octyl
ester of IOX1 should find utility as a starting point for the de-
velopment of JmjC inhibitors and as a use as a cell-permeable
tool compound for studies investigating the roles of 2OG oxy-
genases in epigenetic regulation.
Epigenetic processes regulate gene expression in a context-de-
pendent manner by reversible modifications to chromatin.[1]
An extensive literature documents a wide range of post-trans-
lational histone modifications or “marks” that regulate chroma-
tin accessibility, including acetylation and methylation.[2] His-
tone lysine methylation can activate or repress transcription,
depending on the site and the extent of modification. Some
methylation marks, such as trimethylation of histone-3 lysine-4
(H3K4me3), are associated with transcriptional activation,
whereas other marks, such as H3K9me3, are primarily associat-
ed with transcriptional repression.[3] Although histone methyla-
tion was once considered irreversible, it is now known that,
like acetylation, it is reversible, opening the opportunity for
pharmaceutical intervention.[4]
Two classes of histone lysine demethylases (KDMs) have
been identified, which differ in their catalytic mechanisms. The
lysine-specific demethylases (LSD) employ a flavin-mediated
demethylation.[5] In contrast, the larger class of Jumonji C
domain (JmjC) demethylases catalyse demethylation via initial
methyl group hydroxylation (Scheme 1). The JmjC demethylas-
es belong to the superfamily of FeII and 2-oxoglutarate (2OG)
oxygenases.[6] In contrast to the LSD KDMs, JmjC KDMs accept
all three methylated forms of lysine; their reported substrate
residues include H3K4, H3K9, H3K27 and H3K36.[7] More than
30 human JmjC oxygenases have been identified, some of
which are demethylases with the remainder being hydroxylas-
es.[8, 9] Most of the JmjC proteins contain auxiliary functional
domains, such as prolyl hydroxylase (PHD), Tudor and ZnII
finger domains, which are likely to contribute to substrate se-
lectivity.[10,11] Dysregulation of JmjC demethylases can lead
to aberrant histone methylation states and is associated
with a number of diseases, including cancer and neurological
disorders such as autism and X-linked mental retardation
(XLMR).[12–17] These findings advocate further investigations
into the mechanisms by which these KDMs work, and the de-
velopment of small-molecule chemical probes as tools to eval-
uate their therapeutic potential.
A chemical probe approach offers an advantage over genet-
ic techniques in validating epigenetic targets as it enables tar-
geting of individual domains.[18] Moreover, small-molecule in-
hibitors can be administered in a reversible, dose-dependent
manner, whereas the use of genetic methods is currently less
controllable. Advances in understanding the enzymatic mecha-
nisms and structural elucidation of the JmjC demethylases
have permitted the identification of small-molecule inhibitors,
[a] R. Schiller, Dr. J. R. Wickens, J. T. Bush, Dr. C. Lejeune, Dr. H. Choi,
Dr. T.-L. Yeh, M. C. Chan, Dr. J. S. O. McCullagh, Prof. C. J. Schofield,
Dr. A. Kawamura
Chemistry Research Laboratory, Department of Chemistry
University of Oxford
Mansfield Road, Oxford, OX1 3TA (UK)
E-mail : christopher.schofield@chem.ox.ac.uk
akane.kawamura@chem.ox.ac.uk
[b] Dr. G. Scozzafava, Dr. A. Tumber
Structural Genomics Consortium, Nuffield Department of Medicine
University of Oxford
Old Road Campus, Headington, OX3 7DQ (UK)
[c] Dr. G. Rai, Dr. B. T. Mott, Dr. D. J. Maloney
National Center for Advancing Translational Sciences (NCATS)
National Institutes of Health (NIH)
9800 Medical Centre Drive, Bethesda, MD MSC 3370 (USA)
[d] Dr. A. Kawamura
Wellcome Trust Centre for Human Genetics
University of Oxford
Roosevelt Drive, Oxford, OX3 7BN (UK)
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/cmdc.201300428.
 2014 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of the Creative Commons
Attribution License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited.
 2014 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 566 – 571 566
CHEMMEDCHEM
COMMUNICATIONS
and examples of commonly used 2OG oxygenase inhibitors
are shown in Figure 1.[19–21]
Of these broad-spectrum inhibitors, IOX1 (1) is reported to
be the most potent against a representative panel of 2OG oxy-
genases, including non-JmjC 2OG oxygenases, with an in vitro
IC50 value in the micromolar range. However, its efficacy in
cells is about a hundred-fold lower (HeLa cells, KDM4A, IC50=
86 mm), possibly due to low cell permeability resulting from its
polar C-5 carboxyl group.[23]
With the aim of improving the transmembrane permeability
of IOX1, ester derivatives with different lengths of alkoxy
groups were synthesised (Table 1). Methods for the synthesis
of 5-carboxy-8-quinolinol derivatives have been re-
ported for various uses.[24–26] The Skraup reaction was
employed to synthesise the quinoline IOX1 (1) from
3-amino-4-hydroxybenzoic acid and acrolein. The
ethyl (3), n-butyl (4) and n-octyl (5) ester derivatives
were prepared by Fischer esterification. Methyl ester
2 was synthesised using 5-bromoquinolin-8-ol em-
ploying organopalladium chemistry. To test whether
improved permeability could be obtained by substi-
tution of both phenol and carboxylic acid groups of
IOX1, methyl acetate diester 6 was produced from 2
and acetic anhydride in the presence of catalytic 4-di-
methylaminopyridine. Branched diester derivative 7
was synthesised using the conditions reported by
Nudelman and co-workers.[27,28]
The viability of HeLa cells was analysed after 24 h following
incubation with different concentrations (1–300 mm) of IOX1
(1) or its ester derivatives 2–7 (Table 1; Figure S1 in the Sup-
porting Information). Methyl ester derivative 2 was the most
cytotoxic compound, with a CC50 value of 10 mm. Di-substitut-
ed compounds 6 and 7 had CC50 values of 29 and 17 mm, re-
spectively. Ethyl 3 and n-butyl 4 esters had similar CC50 values
of 50 and 66 mm, respectively. Out of the tested compounds,
only 7 resulted in complete toxicity at the highest concentra-
tion tested, while treatment with the other compounds led to
between 25% and 60% viable cells. n-Octyl ester 5 was not cy-
totoxic in the tested concentration range, with a CC50 value
greater than 300 mm and with over 50% viable cells at the
highest concentration tested. This CC50 value is similar to the
CC50 value obtained here for IOX1 (1) (>300 mm), which is in
agreement with the reported value for IOX1 (292 mm).[21]
Immunofluorescence assays were then used to assess the
effect of IOX1 ester derivatives on demethylation activity in
cells using KDM4A as a representative JmjC KDM.[21] Flag-
tagged KDM4A was transiently overexpressed in HeLa cells,
and these were then treated with either a vehicle control
(DMSO) or varying concentrations (1–300 mm) of IOX1 (1) or
IOX1 ester derivatives 2–7. After 24 h of compound dosing, the
cells were analysed by indirect immunofluorescence
using an anti-Flag tag antibody to identify cells over-
expressing KDM4A, and an antibody for endogenous
H3K9me3 to quantify the level of this histone modifi-
cation, known to be regulated by KDM4A.[7] As a con-
trol, cells overexpressing the H188A catalytically defi-
cient KDM4A variant were also analysed. Treatment
with increasing concentrations of IOX1 (1) or the
ester derivatives caused a dose-response-dependent
increase in H3K9me3 fluorescence intensity, implying
KDM4A inhibition in cells by direct or indirect mecha-
nisms (Figure 2). The cellular EC50 value of 1 was de-
termined to be 100 mm (Table 1), correlating with the
reported value (EC50=86 mm).
[23] The apparent cellular
EC50 values of derivatives 2, 4 and 5 were substantial-
ly lower than that of IOX1 (1), indicating better inhib-
ition of KDM4A activity (Figure S2 in the Supporting
Information). The most potent derivative was n-octyl
Scheme 1. Schematic mechanism for the demethylation of methyl-lysine histone by JmjC
catalysis. JmjC active site residues for FeII coordination are taken from a crystal structure
of human KDM4A in complex with histone H3 peptide trimethylated at Lys9 (PDB:
2OQ6[22]) ; NiII and N-oxalylglycine (NOG) are substitutes for FeII and 2OG, respectively.
Figure 1. 2-Oxoglutarate (2OG) analogues reported as broad-spectrum his-
tone lysine demethylase (KDM) inhibitors : N-oxalylglycine (NOG), and 2,4-
pyridinedicarboxylic acid (2,4-PDCA), IOX1 (1).
Table 1. Structure–activity relationships for IOX1 (1) and its ester derivatives 2–7.
Compd R1 R2 CC50
[a] [mm] EC50
[b] [mm] IC50
[c] [mm]
1 H H >300 100.0 0.6
2 CH3 H 10 50.0 10.7
3 CH2CH3 H 66 >100 14.9
4 (CH2)3CH3 H 50 22.0 5.0
5 (CH2)7CH3 H >300 3.8 3.9
6 CH3 COCH3 29 >100 10.5
7 CH2OCOC(CH3)3 CH2OCOC(CH3)3 17 – >100
[a] CC50 values derived from HeLa cell viability assays. [b] EC50 values derived from im-
munofluorescence assays of KDM4A activity in HeLa cells. [c] IC50 values derived from
AlphaScreen assays of isolated KDM4C. Data represent the mean of n3 replicates
(Figures S1, 2, and 5 in the Supporting Information).
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ester 5 was approximately 30-fold more active than IOX1 (1),
with an EC50 value of 3.8 mm (Figure 2).
An intracellular delivery assay was then performed to com-
pare the cell permeabilities of compounds 1 and 5, as well as
to investigate the level of hydrolysis of 5 to the parent com-
pound (1) in cells. HeLa cells were dosed with IOX1 (1) or n-
octyl ester 5 at a concentration of 200 mm and incubated for
24 h. The intracellular levels of the two forms were then ana-
lysed by LC-MS/MS. Relative quantitative data were collected,
and the compounds were identified by comparing mass and
retention times with values for standards. The n-octyl ester (5)
was found to be more abundant in cells than IOX1 (1) (~ six-
fold) indicating better cell permeability for 5 than 1 (Table 2;
Figure S3 in the Supporting Information). Only a small fraction
(~2%) of 5 was observed to be hydrolysed to the parent com-
pound IOX1 (1). Together with the activities detected in the
cellular assay and with isolated proteins (Table 3), the results of
the intracellular delivery assay indicate that the unhydrolysed
form of 5 accounts for at least some of the KDM inhibitory ac-
tivity observed in cells treated with ester 5.
Interestingly, in cell experiments with 5 analysing for upre-
gulation of the alpha-subunit of the hypoxia-inducible tran-
scription factor (HIF) by inhibition of the 2OG-dependent HIF
hydroxylases, an increase in HIF levels was observed in cells
treated with 5 (Figure S4 in the Supporting Information).[8]
While ester 5 is a relatively poor PHD inhibitor (Table 3), it is
possible that hydrolysis of 5 results in a sufficient amount of
1 to cause PHD inhibition in cells. However, it is also possible
that the HIF upregulation is in part mediated by inhibition of
2OG oxygenases other than PHDs, or by other mechanisms.
Overall, it seems likely that both the hydrolysed (i.e. , IOX1) and
nonhydrolysed forms of 5 contribute to cellular activities.
On the basis of crystallographic analysis, the C-5 carboxylic
acid of IOX1 was proposed to be important for active site
binding, therefore it might be expected that the ester deriva-
tives would be substantially less potent than IOX1.[29] To test
this proposal, we assayed the ability of the compounds to in-
hibit the H3K9me3 demethylation activity of isolated KDM4C
using an amplified luminescent proximity homogeneous assay
(ALPHA) screen.[30] For IOX1 (1), an IC50 value of 0.6 mm was ob-
tained, identical to that reported in the literature (Table 1; Fig-
ure S5 in the Supporting Information).[23] Apart from the bulky
di-tert-butyl diacetate derivative, 7, the esters displayed similar
activities in the micromolar range, with 5 being the most
potent (IC50=3.9 mm). n-Octyl ester 5 was shown to be stable
to hydrolysis in the AlphaScreen buffer according to LC-MS
analysis (Figure S6 in the Supporting Information). The activity
of derivative 5 and of the other esters, as determined by the
AlphaScreen assay, indicates that the C-5 ester derivatisation
can be tolerated, while preserving some KDM inhibitory activi-
ty.
IOX1 analogues with lipophilic substitution of the C-5 car-
boxylic acid have been reported to inhibit JmjC proteins.[21,31]
Docking simulations were performed to explore the rationale
behind the structure–activity relationships observed in the Al-
phaScreen assays (Table 1). These simulations included IOX1
esters, with linear alkyl chains ranging in length between one
and ten carbons, docked into the X-ray crystal structure of the
KDM4A active site in complex with IOX1 (PDB: 3NJY[21]). The
docking results indicate that the KDM4A active site can accom-
modate IOX1 ester derivatives including n-octyl and even n-
decyl esters (Figure 3; Figure S7 in the Supporting Informa-
tion). In agreement with the AlphaScreen results, IOX1 exhibit-
ed the strongest predicted binding to the active site as de-
duced by the calculated Gibbs free energy (DG=7.05 Kcal
mol1; Table S1 in the Supporting Information). The shorter
esters, with one or two carbons, had IC50 values of >10 mm in
the AlphaScreen and calculated DG values of greater than
6.5 Kcalmol1 indicating weaker binding compared with
IOX1. The longer esters, with three to ten carbons, had IC50
values of 5 mm in the AlphaScreen and calculated DG values
lower than 6.5 Kcalmol1. This improved binding indicated
by the docking simulations correlates with higher potency in
the AlphaScreen and could be explained by a hydrophobic
effect. Increasing the length of the alkyl chain is likely to in-
crease the binding affinity to the hydrophobic region leading
to the active site, where the aliphatic ester chain is accommo-
Figure 2. n-Octyl ester 5 increases H3K9me3 levels in HeLa cells via KDM4A
inhibition. Indirect immunofluorescence assays with anti-Flag (green) and
anti-H3K9me3 (red) antibodies and with DAPI staining (blue) in HeLa cells
overexpressing Flag-tagged KDM4A. DMSO treatment has no effect on
KDM4A demethylase activity, while IOX1 (1) (300 mm) and n-octyl ester 5
(10 mm) treatment resulted in increased H3K9Me3 substrate levels (white
arrows indicate transfected cells). The H188A catalytically inactive KDM4A
variant does not affect H3K9Me3 levels.
Table 2. Intracellular delivery of IOX1 (1) and n-octyl ester 5.[a]
Dosed compd Lysate concentration [fmol cell1]
IOX1 (1) n-Octyl ester (5)
IOX1 (1) 0.6240.134 0.0300.001
n-Octyl ester 5 0.0800.006 4.0831.290
[a] IOX1 (1) and n-octyl ester 5 were detected in the lysates of HeLa cells
24 h after the administration of IOX1 (1) or n-octyl ester 5 at a concentra-
tion of 200 mm; data represent the meanSD of n=3 replicates.
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dated. These docking observations combined with the struc-
ture–activity data may be useful in the structure-based identifi-
cation of new JmjC inhibitors.
A more extended set of AlphaScreen assays were then used
to compare the selectivity of n-octyl ester 5 with that of IOX1
(1) and the shorter ester derivatives (methyl ester 2 and n-
butyl ester 4) against additional 2OG oxygenases. The assays
were performed using representatives of different JmjC KDM
subfamilies (KDM4C, KDM4E, KDM2A, KDM3A, KDM5C and
KDM6B) and the catalytic domain of a HIF prolyl hydroxylase
(PHD2). The results support the classification of IOX1 (1) as
a broad-spectrum 2OG oxygenase inhibitor, with IC50 values in
the micromolar range against all of the tested oxygenases
(Table 3; Figure S8 in the Supporting Information).[23] Modifica-
tion of IOX1 to methyl ester 2 gave an apparently nonselective
increase in IC50 values. Increasing the length of the ester alkoxy
group to four carbons (as in 4) created apparent selectivity to-
wards a subset of the JmjC KDMs, and in particular the KDM4
subfamily. Further increasing the length of the alkoxy-group to
eight carbons (as in 5) narrowed the observed inhibitory activi-
ty to the KDM4 subfamily ; specifically, KDM4C was the most
potently inhibited enzyme.
The apparent relative selectivity of 5 for the KDM4 subfami-
ly, at least compared with the parent IOX1 (1), might be due to
differences in the active sites of the JmjC proteins; crystallo-
graphic evidence implies that the active site opening of the
KDM4 demethylases is larger than that of other JmjC subfami-
lies, and in particular compared with the narrow binding
pocket of the PHD family of hydroxylases.[28–30] This initial char-
acterisation suggests that an appropriate substitution of the
IOX1 C-5 position could enable the generation of potent and
selective JmjC KDM inhibitors that are active in cells.
In conclusion, we have shown that C-5 ester derivatives of
IOX1 can retain JmjC KDM inhibitory activity. Of the tested
esters, n-octyl derivative 5 was the most potent in vitro against
KDM4C. In cells, ester 5 was the least cytotoxic of the tested
compounds and the most potent inhibitor of H3K9me3 deme-
thylation (EC50=3.8 mm). This is likely to be, at least in part,
due to improved cell permeability of 5 compared with that of
1, as detected in an intracellular delivery assay. Interestingly, it
seems that 5 is not, at least efficiently, hydrolysed in HeLa
cells, though esterases are known to be present and there are
reported examples of short-chain ester hydrolysis.[32,33] Thus, it
seems likely that at least some of the cellular activity of 5
results from inhibition by the intact ester form.
Docking studies based on crystallographic analysis with
IOX1 support the viability of n-octyl ester 5 binding KDM4,
with the alkyl group occupying part of a region leading to the
active site. It is notable that some other histone demethylase
and deacetylase inhibitors reported in the literature contain an
aliphatic chain, two examples with an n-octyl group as in 5,
possibly reflecting a general binding of aliphatic groups in this
region.[34–37] Binding energies as calculated by docking simula-
tions were found to correlate reasonably well with the Al-
phaScreen inhibition results and provide a possible explana-
tion for the increased potency of esters with a long alkyl chain.
An extended AlphaScreen with JmjC KDMs and PHD2 as
a prolyl hydroxylase representative indicates that increasing
the ester chain length to four carbons improves the selectivity
towards JmjC KDMs. Most importantly, a chain length of eight
carbons—as in derivative 5—creates selectivity towards the
KDM4 subfamily.
The activity of 5 raises the question as to whether other
available ester prodrugs of JmjC inhibitors, such as NOG, 2,4-
Figure 3. Docking of n-octyl ester 5 in the KDM4A active site using a crystal
structure of KDM4A bound to IOX1 (PDB: 3NJY[21]). a) Overlay of the docked
position of n-octyl ester 5 (pink) with that observed for IOX1 (yellow); b) Sur-
face view of modelled 5 in the active site pocket.
Table 3. In vitro selectivity of IOX1 (1) and its methyl (2), n-butyl (4) and
n-octyl (5) ester derivatives for JmjC subfamilies.
Protein IC50 [mm]
[a]
1 2 4 5
KDM4C 0.6 10.7 5.0 3.9
KDM4E 2.3 12.8 6.3 45.0
KDM2A 1.8 30.1 16.3 >100
KDM3A 0.1 14.5 29.4 >100
KDM5C 19.0 34.9 >100 >100
KDM6B 1.4 10.8 >100 >100
PHD2 33.0 41.1 >100 >100
[a] IC50 values derived from in vitro AlphaScreen assays. Data represent
the mean of n=4 replicates (Figure S8 in the Supporting Information).
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PCDA, GSK-J4, methylstat and 2-hydroxyglutarate, could also
be active in their ester forms, and whether systematic ester
derivatisation could lead to increased cellular poten-
cies.[19,20, 34,38,39] It is important to note, however, that the results
with different 2OG oxygenases reveal that ester derivatisation
of IOX1, and possibly of other broad-spectrum KDM inhibitors
including the aforementioned compounds, may confer selec-
tivity not apparent in the parent inhibitor.
We hope 5 will find use as a starting point for the develop-
ment of new JmjC inhibitors as well as a cell-permeable tool
compound in studies investigating the role of JmjC histone
demethylases as therapeutic targets.
Experimental Section
Experimental details of the synthesis and characterisation, in vitro
assays and cell-based studies, as well as supplementary figures, are
given in the Supporting Information available via http://dx.doi.org/
10.1002/cmdc.201300428.
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